The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of mitiperstat

The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of mitiperstat

Aims Mitiperstat is a novel, highly potent myeloperoxidase inhibitor being evaluated in patients with cardio‐metabolic disease (phase 2). These patients often have impaired renal function, which may affect mitiperstat pharmacokinetics. This study assessed mitiperstat pharmacokinetics, safety and tol...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of clinical pharmacology 2024-12, Vol.90 (12), p.3212-3220
Hauptverfasser: Bhattacharya, Chandrali S., Pizzato, Patricia Ely, Heijer, Maria, Sunnåker, Mikael, Holden, Julie, Trebski, Monika, Nelander, Karin, Ali, Hodan, Genov, Diyan K., Aurell, Malin, Collén, Anna, Ericsson, Hans
Format: Artikel
Sprache:eng
Schlagworte:
Administration, Oral
Adult
Aged
Aged, 80 and over
Area Under Curve
AZD4831
Female
Glomerular Filtration Rate - drug effects
Half-Life
heart failure
Humans
kidney disease
Male
Metabolic Clearance Rate
Middle Aged
mitiperstat
Original
Peroxidase
pharmacokinetics
renal impairment
Renal Insufficiency - metabolism
Severity of Illness Index
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Aims Mitiperstat is a novel, highly potent myeloperoxidase inhibitor being evaluated in patients with cardio‐metabolic disease (phase 2). These patients often have impaired renal function, which may affect mitiperstat pharmacokinetics. This study assessed mitiperstat pharmacokinetics, safety and tolerability in participants with severe renal impairment and normal renal function, to inform inclusion of participants with estimated glomerular filtration rate (eGFR) 
ISSN:0306-5251
1365-2125
1365-2125
DOI:10.1111/bcp.16205